HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection

Vaccine

Volumn 29, Issue 11, 2011, Pages 2011-2014

  Kemp, Troy J ^a   Hildesheim, Allan ^b   Safaeian, Mahboobeh ^b   Dauner, Joseph G ^a   Pan, Yuanji ^a   Porras, Carolina ^c   Schiller, John T ^b   Lowy, Douglas R ^b   Herrero, Rolando ^c   Pinto, Ligia A ^a  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

Author keywords

Antibody; Human papillomavirus; Vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; WART VIRUS VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BOVINE PAPILLOMAVIRUS TYPE 1; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS PROTECTION; CROSS REACTION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; PAPILLOMAVIRUS INFECTION; PHYLOGENY; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; VACCINATION; VIRUS TYPING;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CROSS PROTECTION; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 79951812752     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.001     Document Type: Article

References (13)

1. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(July (9686)):301-314.
2. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006, 95(December (11)):1459-1466.
3. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199(April (7)):926-935.
4. Breitburd F., Kirnbauer R., Hubbert N.L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995, 69(June (6)):3959-3963.
5. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 1995, 92(December (25)):11553-11557.
6. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364(November (9447)):1757-1765.
7. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6(May (5)):271-278.
8. Pinto L.A., Viscidi R., Harro C.D., Kemp T.J., Garcia-Pineres A.J., Trivett M., et al. Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology 2006, 353(September (2)):451-462.
9. Smith J.F., Brownlow M., Brown M., Kowalski R., Esser M.T., Ruiz W., et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007, 3(July-August (4)):109-115.
10. Herrero R., Hildesheim A., Rodriguez A.C., Wacholder S., Bratti C., Solomon D., et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008, 26(September (37)):4795-4808.
11. Hildesheim A., Herrero R., Wacholder S., Rodriguez A.C., Solomon D., Bratti M.C., et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007, 298(August (7)):743-753.
12. Kemp T.J., Garcia-Pineres A., Falk R.T., Poncelet S., Dessy F., Giannini S.L., et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 2008, 26(July (29-30)):3608-3616.
13. David M.-P., Van Herck K., Hardt K., Tibaldi F., Dubin G., Descamps D., et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol 2009, 115(3 (Suppl. 1)):S1-S6.